SCHEMBL4986281

SCHEMBL4986281

C[C@H]1CNCC[C@@]12OC(=O)c1ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.41
REN P00797 2/20 0.41
KCNH2 Q12809 2/20 0.41
CFTR P13569 1/20 0.37
GOPC Q9HD26 1/20 0.37
NPSR1 Q6W5P4 3/20 0.35
GAA P10253 1/20 0.35
NPY5R Q15761 6/20 0.35
LMNA P02545 2/20 0.35
HTR2C P28335 2/20 0.35
SIGMAR1 Q99720 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2B P41595 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
POLB P06746 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ESR1 P03372 1/20 0.34
TP53 P04637 1/20 0.34
TYMS P04818 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2210767 1.00 CYP3A4 (0.41) CYP3A4RENKCNH2CFTRGOPC
SCHEMBL11962123 0.80 REN (0.47) CYP3A4RENKCNH2NPY5RHTR2C
SCHEMBL4361753 0.76 CFTR (0.41) CYP3A4CFTRGOPCNPSR1GAA
SCHEMBL4361755 0.76 CFTR (0.41) CYP3A4CFTRGOPCNPSR1GAA
SCHEMBL471208 0.71 ATM (0.45) KCNH2HTR2CSIGMAR1HTR2AHTR2B
SCHEMBL171980 0.70 SIGMAR1 (0.54) CFTRGOPCNPY5RSIGMAR1
SCHEMBL29674557 0.70 SIGMAR1 (0.54) CFTRGOPCNPY5RSIGMAR1
Hydrochloric Acid SCHEMBL2002554 0.69 SIGMAR1 (0.52) NPY5RSIGMAR1
SCHEMBL3223126 0.68 SIGMAR1 (0.48) CFTRGOPCNPY5RSIGMAR1HTR2A
SCHEMBL350821 0.68 SIGMAR1 (0.48) CFTRGOPCNPY5RSIGMAR1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2535329-A2 Spiro-piperidine derivatives F. Hoffmann-La Roche AG (CH) 2012-12-19 EP disclosed
US-8084609-B2 Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases HOFFMAN-LA ROCHE INC. (US) 2011-12-27 US disclosed
US-20080153862-A1 SPIROPIPERIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 US disclosed
US-20080153861-A1 SPIROPIPERIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 US disclosed
US-20080153863-A1 SPIROPIPERIDINE DERIVATIVES HOFFMAN-LA ROCHE INC. 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153863-A1 SPIROPIPERIDINE DERIVATIVES AVPR1A, AVPR1B, AVPR2 CYP3A4 1254/4885REN 29/4885KCNH2 289/4885
US-20080153861-A1 SPIROPIPERIDINE DERIVATIVES AVPR1A, AVPR1B, AVPR2 CYP3A4 1254/4885REN 29/4885KCNH2 289/4885
US-20080153862-A1 SPIROPIPERIDINE DERIVATIVES AVPR1A, AVPR1B, AVPR2 CYP3A4 1254/4885REN 29/4885KCNH2 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.